3245-63-4

Usage

InChI:InChI=1/C13H19BrO/c1-13(2,3)11-5-7-12(8-6-11)15-10-4-9-14/h5-8H,4,9-10H2,1-3H3

Upstream product

• 98-54-4 para-tert-butylphenol 
• 109-64-8 1,3-dibromo-propane 
• 627-18-9 1-bromo-3-propanol 

Downstream Products

• 171369-22-5 1-Benzyloxy-3,5-bis-[3-(4-tert-butyl-phenoxy)-propoxy]-benzene 
• 239447-21-3 {3,5-bis-[3-(4-tert-butyl-phenoxy)-propoxy]-phenyl}-methanol 
• 1160122-14-4 1-[3-(3-(4-tert-butylphenoxy)propoxy)propyl]-3-methylpiperidine 
• 1160122-17-7 1-[3-(3-(4-tert-butylphenoxy)propoxy)propyl]-4-methylpiperidine 
• 1160122-20-2 1-[3-(3-(4-tert-butylphenoxy)propoxy)propyl]azepane 
• 401802-36-6 C₁₇H₂₈N₂O 
• 1217339-63-3 2-(3-(4-(tert-butyl)phenoxy)propyl)isoindoline-1,3-dione 
• 1566528-28-6 C₂₇H₃₃FN₂O₃ 
• 1566528-04-8 5-(3-(4-(tert-butyl)phenoxy)propyl)-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole 
• 2299-54-9 N-<2-(2-Methoxy-phenoxy)-aethyl>-3-(4-tert-butyl-phenoxy)-propylamin 

Relevant academic research and scientific papers

Dual target ligands with 4-tert-butylphenoxy scaffold as histamine H3 receptor antagonists and monoamine oxidase B inhibitors

Dual target ligands are a promising concept for the treatment of Parkinson’s disease (PD). A combination of monoamine oxidase B (MAO B) inhibition with histamine H3 receptor (H3R) antagonism could have positive effects on dopamine re

Viologen-cucurbituril host/guest chemistry - redox control of dimerizationversusinclusion

Two calix[4]arene systems,C234+andC244+- where 2 corresponds to the number of viologen units and 3-4 corresponds to the number of carbon atoms connecting the viologen units to the macrocyclic core - have been synthesized and led to t

Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H3R ligands

As a continuation of our search for novel histamine H3 receptor ligands, a series of twenty four new tert-butyl and tert-pentyl phenoxyalkylamine derivatives (2?25) was synthesized. Compounds with three to four carbon atoms alkyl chain spacer were evaluated for their binding properties at human histamine H3 receptor (hH3R). The highest affinities were observed for 4-pyridyl derivatives 4, 10, 16 and 22 (Ki = 16.0–120 nM). As it has been shown in docking studies, those specific heteroaromatic 4-N piperazine substituents might interact with one of the key receptor interacting amino acids. Moreover, the most promising compounds exhibited anticonvulsant activity in the maximal electroshock-induced seizure (MES) model in mice. Furthermore, the blood-brain barrier penetration, the functional H3R antagonist potency as well as the pro-cognitive properties in the passive avoidance test were demonstrated for compound 10. In order to estimate drug-likeness of compound 10, in silico and experimental evaluation of metabolic stability in human liver microsomes was performed. In addition, paying attention to the results obtained within this study, the 4-pyridyl-piperazino moiety has been established as a new bioisosteric piperidine replacement in H3R ligands.

Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors

Myeloid cell leukemia-1 (Mcl-1) is an important antiapoptotic protein functioning through protein-protein interactions. We discovered LSL-A6 (2-((2-carbamoyl-1-(3-(4-methoxyphenoxy)propyl)-1H-indol-6-yl)oxy)acetic acid) with a novel N-substituted indole scaffold to interfere Mcl-1 binding as a novel Mcl-1 inhibitor. Molecular modeling indicated that this compound binds with Mcl-1 by interaction with P2 and R263 hot-spots. Structure modification focused on several moieties including indole core, hydrophobic tail and acidic chain were conducted and structure-activity relationship was analyzed. The most potent compound 24d which exhibited Ki value of 110?nM for interfering Mcl-1 binding was obtained after hit-to-lead modification.

Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors

A novel series of dihydro-1,3,5-triazine derivatives bearing a heteroatom spiro-ring were designed and synthesized on the basis of molecular flexible docking work, and their biological activities were evaluated. Compounds A2, A5, B1 and B3 showed potent human dihydrofolate reductase (hDHFR) inhibitory activity with IC50values of 7.46 nM, 3.72 nM, 6.46 nM, 4.08 nM, versus reference drug methotrexate (MTX). From the molecular docking result we concluded that the conformation space generated by deformation of the flexible residue Phe31 is favorable for the binding of the spiro-ring, and inserting heteroatom into spiro ring might increase the binding affinity. There were 24 compounds with broadspectrum antiproliferative activity against several tumor cell lines (HCT116, A549, HL-60, HepG2 and MDA-MB-231) with IC50values ranging from 0.79 to 0.001 μM. The antitumor activity in?vivo of compound A2 was determined in a human alveolar basal epithelial cell line A549 xenograft model. This study offered novel anticancer agents with high inhibitory activity that target hDHFR and have a binding mode of the novel molecular scaffold with hDHFR. This provides potent support for further development of novel hDHFR inhibitors.

Diamino triazines derivatives, their salts, preparation method, composition and use thereof

The invention discloses derivatives and salts of damino dihydrotriazine, and a preparation method, a composition and application thereof. According to the invention, the preparation method of the damino dihydrotriazine derivative and the damino dihydrotriazine salt can be realized by adopting a method I or a method II, wherein the method I includes the step of obtaining a general formula I compound prepared through the reaction between a general formula IV compound and a general formula V compound, while the method II includes the step of mixing a general formula VIII compound with a general formula II compound under an acidic condition, and obtaining the compound shown in the general formula I through a cyclization reaction of the mixture. The invention also provides application of derivatives and salts of the damino dihydrotriazine in preparation of human dihydrofolate reductase inhibitors, preventing and curing drugs for tumor or bacterial infection diseases. The invention further provides a drug composition, which comprises an effective amount of the derivatives and/or salts of the damino dihydrotriazine, as well as pharmaceutically acceptable carriers. According to the invention, spiro heterocyclic ring derivatives of the damino dihydrotriazine have an excellent inhibitory activity on human dihydrofolate reductase, tumor cells and bacteria.

ω-Phenoxyalkyl substituted bis(indenyl)zirconium dichloride complexes as catalysts for homogeneous ethylene polymerization

Nine bis(indenyl)zirconium dichloride complexes of the type [C9H6-(CH2)n-O-Ar]2ZrCl2 (n = 3-5; Ar = Ph, t-Bu-Ph) were synthesized, characterized, activated with methylalumoxane (MAO) and tested for ethylene polymerization. Structure-property-relationship studies showed that the activities of the catalysts depend on the length of the bridging chain between the indenyl and the phenoxy group as well as on the bulk at the phenoxy substituent. A t-Bu substituent at the ortho position of the phenoxy group (5a/MAO) gives a much higher catalyst activity (27,500 kg PE/mol cat h) than the isomer 8a/MAO with a t-Bu substituent at the para position of the phenoxy group (16,700 kg PE/mol cat h). Obviously substituents in the ortho position of the phenyl ring generate a bulkier catalyst cation and this can keep the MAO anion at a further distance to allow easier ethylene coordination and chain growth in the polymerization steps. The mono substituted bis(indenyl) complex (C9H7)[C9H6-(CH2)4-O-4-t-Bu]ZrCl2 shows lower activity (11,700 kg PE/mol cat h) than 8a indicating that the electronic effect is dominating in this type of catalysts.

Novel Carboline Derivatives as Potent Antifungal Lead Compounds: Design, Synthesis, and Biological Evaluation

A series of novel antifungal carboline derivatives was designed and synthesized, which showed broad-spectrum antifungal activity. Particularly, compound C38 showed comparable in vitro antifungal activity to fluconazole without toxicity to human embryonic lung cells. It also exhibited good fungicidal activity against both fluconazole-sensitive and -resistant Candida albicans cells and had potent inhibition activity against Candida albicans biofilm formation and hyphal growth. Moreover, C38 showed good synergistic antifungal activity in combination with fluconazole (FLC) against FLC-resistant Candida species. Preliminary mechanism studies revealed that C38 might act by inhibiting the synthesis of fungal cell wall.

Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes

Two series of triazaspiroalkanedienes, bearing a substituted phenoxy propyloxy side chain, were identified as potent mammalian DHFR inhibitors. One series has a 6,5-spiro bicyclic ring system and the other series has a 6,6-spiro bicyclic system. Both seri

Improved model of lanosterol 14α-demethylase by ligand-supported homology modeling: Validation by virtual screening and azole optimization

Lanosterol 14α-demethylase (CYP51) is an important target for antifungal drugs. An improved three-dimensional model of CYP51 from Candida albicans (CACYP51) was constructed by ligand-supported homology modeling and molecular dynamics simulations. The accuracy of the constructed model was evaluated by its performance in a small-scale virtual screen. The results show that known CYP51 inhibitors were efficiently discriminated by the model, and it performed better than our previous CACYP51 model. The active site of CACYP51 was characterized by multiple copy simultaneous search (MCSS) calculations. On the basis of the MCSS results, a series of novel azoles were designed and synthesized, and they showed good in vitro antifungal activity with a broad spectrum. The MIC80 value of four of these compounds against C. albicans is 0.001 μgmL-1, indicating that they are promising leads for the discovery of novel antifungal agents.